AstraZeneca cuts a couple of late-stage life-cycle trials after disappointing efficacy
AstraZeneca said it had stopped several mid- and late-stage trials of some of its pipeline programs in the past few months, potentially limiting some of the life-cycle extensions it was hoping for. Its first-quarter
April 29, 2026 06:50 AM EDT R&DPharma AstraZeneca cuts a couple of late-stage life-cycle trials after disappointing efficacy Elizabeth Cairns Senior biopharma journalist AstraZeneca said it had stopped several mid- and late-stage trials of some of its pipeline programs in the past few months, potentially limiting some of … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that